Taiyin Yang, PhD

药物开发及生产 执行副总裁

Taiyin Yang serves as Executive Vice President of Pharmaceutical Development and Manufacturing with responsibility for all the company's investigational compounds and marketed products. Under her leadership, Gilead developed the world's first HIV single tablet regimen and advanced more than 25 compounds from early-stage development to market, reaching millions of people around the world.

Prior to joining Gilead in 1993, Taiyin worked in analytical chemistry at Syntex Corp.

She received her bachelor's degree in chemistry from National Taiwan University and her PhD in organic chemistry from the University of Southern California.